Piper Sandler Issues Positive Forecast for ICU Medical (NASDAQ:ICUI) Stock Price

ICU Medical (NASDAQ:ICUI) had its price target lifted by Piper Sandler from $163.00 to $195.00 in a report published on Friday,Benzinga reports. Piper Sandler currently has an overweight rating on the medical instruments supplier’s stock.

Several other analysts also recently issued reports on ICUI. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. KeyCorp increased their price target on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Needham & Company LLC boosted their price objective on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Stock Up 10.9%

NASDAQ ICUI opened at $184.56 on Friday. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. ICU Medical has a 52 week low of $107.00 and a 52 week high of $192.85. The firm has a market capitalization of $4.61 billion, a price-to-earnings ratio of 156.41, a PEG ratio of 2.32 and a beta of 0.74. The company has a fifty day moving average of $151.64 and a two-hundred day moving average of $141.02.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.94%. The business had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same quarter in the prior year, the firm posted $2.10 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, analysts predict that ICU Medical will post 6.51 earnings per share for the current year.

Insider Buying and Selling

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the sale, the vice president owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the sale, the director directly owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

Several hedge funds have recently modified their holdings of ICUI. Norges Bank purchased a new stake in ICU Medical during the fourth quarter valued at approximately $58,083,000. Kirr Marbach & Co. LLC IN increased its holdings in shares of ICU Medical by 18.4% during the first quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock valued at $5,702,000 after acquiring an additional 6,863 shares in the last quarter. F m Investments LLC increased its holdings in shares of ICU Medical by 33.3% during the fourth quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock valued at $6,637,000 after acquiring an additional 11,608 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of ICU Medical by 1,604.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after purchasing an additional 285,648 shares during the last quarter. Finally, Fifth Third Bancorp raised its position in shares of ICU Medical by 26,365.6% in the 1st quarter. Fifth Third Bancorp now owns 43,139 shares of the medical instruments supplier’s stock valued at $5,571,000 after purchasing an additional 42,976 shares during the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.